All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
GW 572016
Known as:
GW-572016
, GW572016
Â
Â
Topic mentions per year
Topic mentions per year
2002-2012
0
5
10
15
2002
2012
Related topics
Related topics
2 relations
Broader (2)
lapatinib
lapatinib ditosylate
Related mentions per year
Related mentions per year
1979-2018
1970
1980
1990
2000
2010
2020
GW 572016
lapatinib
lapatinib ditosylate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3…
Joseph W. Polli
,
Katie L. Olson
,
+6 authors
Victoria E. Demby
Drug metabolism and disposition: the biological…
2009
Lapatinib is a tyrosine kinase inhibitor approved for use in combination with capecitabine to treat advanced or metastatic breast…Â
(More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Chun-Ling Dai
,
Amit Mani Kumar Tiwari
,
+12 authors
Liwu Fu
Cancer research
2008
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor…Â
(More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour…
David W Rusnak
,
Krystal J Alligood
,
+8 authors
Terri Gilmer
Cell proliferation
2007
OBJECTIVE Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR…Â
(More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Gottfried E. Konecny
,
Mark Pegram
,
+12 authors
Dennis J. Slamon
Cancer research
2006
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here…Â
(More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients…
Howard A. Burris
,
Herbert I. Hurwitz
,
+13 authors
Neil L. Spector
Journal of clinical oncology : official journal…
2005
PURPOSE This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with…Â
(More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
Wenle Xia
,
Catherine M. Gerard
,
Leihua Liu
,
Nathalie M Baudson
,
Thierry L Ory
,
Neil L. Spector
Oncogene
2005
Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of…Â
(More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Isabel M. Chu
,
Kimberly L. Blackwell
,
Susie A Chen
,
Joyce M Slingerland
Cancer research
2005
Effective treatment of estrogen receptor (ER)-positive breast cancers with tamoxifen is often curtailed by the development of…Â
(More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Todd A. Carter
,
Lisa M Wodicka
,
+19 authors
David J Lockhart
Proceedings of the National Academy of Sciences…
2005
To realize the full potential of targeted protein kinase inhibitors for the treatment of cancer, it is important to address the…Â
(More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Edgar R. Wood
,
Anne T Truesdale
,
+11 authors
Lisa M. Shewchuk
Cancer research
2004
GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of…Â
(More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
Wenle Xia
,
Robert J. Mullin
,
+6 authors
Neil L. Spector
Oncogene
2002
Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR…Â
(More)
Is this relevant?